000			02040 a2200565 4500
005			20250515224726.0
264		0	_c20100617
008			201006s 0 0 eng d
022			_a0888-5109
024	7		_a10.4140/TCP.n.2010.199 _2doi
040			_aNLM _beng _cNLM
100	1		_aNwachukwu, Ugo
245	0	0	_aHealth trends. _h[electronic resource]
260			_bThe Consultant pharmacist : the journal of the American Society of Consultant Pharmacists _cApr 2010
300			_a199-202 p. _bdigital
500			_aPublication Type: Journal Article
650	0	4	_aAdolescent
650	0	4	_aAdult
650	0	4	_aAge Factors
650	0	4	_aAged
650	0	4	_aAged, 80 and over
650	0	4	_aBlood Glucose _xdrug effects
650	0	4	_aBone Density Conservation Agents _xtherapeutic use
650	0	4	_aChemotherapy, Adjuvant
650	0	4	_aColonic Neoplasms _xdrug therapy
650	0	4	_aDiabetes Mellitus, Type 2 _xblood
650	0	4	_aDiphosphonates _xtherapeutic use
650	0	4	_aDrug Therapy _xtrends
650	0	4	_aDyslipidemias _xdrug therapy
650	0	4	_aEnoxaparin _xtherapeutic use
650	0	4	_aFibrinolytic Agents _xtherapeutic use
650	0	4	_aFractures, Bone _xprevention & control
650	0	4	_aGlycated Hemoglobin _xmetabolism
650	0	4	_aHumans
650	0	4	_aHypoglycemic Agents _xtherapeutic use
650	0	4	_aHypolipidemic Agents _xtherapeutic use
650	0	4	_aImidazoles _xtherapeutic use
650	0	4	_aMiddle Aged
650	0	4	_aNeoplasm Staging
650	0	4	_aPharmacy _xtrends
650	0	4	_aPyrazoles _xtherapeutic use
650	0	4	_aPyridones _xtherapeutic use
650	0	4	_aSalicylates _xtherapeutic use
650	0	4	_aTreatment Outcome
650	0	4	_aVenous Thromboembolism _xprevention & control
650	0	4	_aYoung Adult
650	0	4	_aZoledronic Acid
773	0		_tThe Consultant pharmacist : the journal of the American Society of Consultant Pharmacists _gvol. 25 _gno. 4 _gp. 199-202
856	4	0	_uhttps://doi.org/10.4140/TCP.n.2010.199 _zAvailable from publisher's website
999			_c19863334 _d19863334